Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

New Onset: early-phase trial registry

1 of 1 indexed New Onset trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

New Onset: 1 US clinical trial tracked, 1 recruiting.

New Onset is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 1 of these trials.

Enrollment posture brief

Registry condition new-onset

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

New Onset (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near New Onset

New Onset lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for New Onset on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. New Onset is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on New Onset records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

verapamil extended-release capsule Drug
1 trials
Anti-thymocyte globulin (ATG) Drug
1 trials
Adalimumab Drug
1 trials

US sites by state

Facility locations filed on New Onset trials. A trial with sites in several states counts in each.

Washington 1 trials
Texas 1 trials
Pennsylvania 1 trials
New York 1 trials
Minnesota 1 trials
Indiana 1 trials
Florida 1 trials
Connecticut 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this New Onset page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This New Onset condition card totals 1 registered trials; most-linked intervention verapamil extended-release capsule; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.